Gain Therapeutics (NASDAQ:GANX – Get Free Report)‘s stock had its “outperform” rating reissued by stock analysts at Oppenheimer in a note issued to investors on Tuesday, Benzinga reports. They currently have a $9.00 price objective on the stock. Oppenheimer’s price target indicates a potential upside of 182.13% from the company’s previous close.
A number of other brokerages have also recently commented on GANX. Chardan Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Gain Therapeutics in a research note on Wednesday, March 27th. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Gain Therapeutics in a research note on Monday, April 1st.
View Our Latest Stock Report on Gain Therapeutics
Gain Therapeutics Price Performance
Gain Therapeutics (NASDAQ:GANX – Get Free Report) last issued its quarterly earnings data on Tuesday, March 26th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03. Analysts expect that Gain Therapeutics will post -1.17 EPS for the current year.
Insider Activity at Gain Therapeutics
In related news, Director Jeffrey Scott Riley purchased 30,000 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The shares were purchased at an average price of $3.86 per share, with a total value of $115,800.00. Following the purchase, the director now owns 30,000 shares of the company’s stock, valued at $115,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 11.00% of the stock is owned by corporate insiders.
About Gain Therapeutics
Gain Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.
Featured Articles
- Five stocks we like better than Gain Therapeutics
- What Are the FAANG Stocks and Are They Good Investments?
- High-Yield Texas Instruments Could Hit New Highs Soon
- Manufacturing Stocks Investing
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- How to invest in marijuana stocks in 7 steps
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.